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Abstract
Atherosclerosis previously defined as an obstructive disease leads to fatty deposits in the 
arterial wall. Nowadays, according to the best of our knowledge, specific cells, molecular 
mechanisms, and genes play crucial roles in the pathogenesis of the disease. Inflammatory 
reaction contributes to atherosclerotic lesion formation, since fatty streak leads to a plaque 
erosion or rupture. Experimental and clinical studies have shown that besides well-known 
risk factors, such as smoking, hypertension, diabetes, and dyslipidemia, genetic variations in 
certain locuses affect the disease burden. A common genetic variability at the apoE locus has 
been shown to be associated with a risk for cardiovascular disease. In many studies, a higher 
cardiovascular risk has been associated with the presence of the apo ε4 allele, whereas the 
apo ε2 allele has been protective. Recent studies stated that pro-inflammatory cytokines 
increase the binding of low-density lipoprotein (LDL) to endothelium and smooth muscle 
cells, so inflammatory response solely increases lipoprotein accumulation within the vessel 
wall. As a conclusion, cholesterol accumulation leads to atherosclerotic plaque via several 
mechanisms. Genetic predisposition and inflammatory process may affect disease severity.
Keywords: vascular inflammation, apoE, Lp-PLA2, LDL subtypes, endothelial 
dysfunction
1. Introduction
Cholesterol is one of the important molecules of the organism due to its strong relationship 
with cardiovascular disease. In clinical practice, the term of lipids is mainly used instead of 
lipoprotein metabolism because of its association with atherosclerosis. Certain lipoprotein 
fractions lead to the deposition and retention of cholesterol in the vessel wall causing athero-
sclerosis. Different guidelines recommend that lowering plasma cholesterol level by diet or 
drugs results in the reduction in cardiovascular disease.
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Cholesterol is a hydrophobic macromolecule, transported in the circulation by lipoproteins 
such as chylomicrons, very low-density lipoprotein (VLDL), and high-density lipoprotein 
(HDL). Low-density lipoprotein (LDL) and intermediate-density lipoprotein (IDL) are syn-
thesized from VLDL. Cholesterol, which is taken from the diet, is absorbed from the intestine 
and transported via chylomicrons to the liver. In the liver, endogen lipids with cholesterol 
are packaged into VLDL and secreted to bloodstream. LDL is responsible for peripheral 
cholesterol transport. Lipoproteins contain different proportions of lipids and proteins and 
have different physical and chemical properties. Apolipoproteins (apo) are the protein com-
ponents of lipoproteins. Each lipoprotein class differs by its apoprotein content and propor-
tions. ApoB100 is the main apoprotein of LDL and VLDL. ApoA-I and ApoA-II are the main 
apoproteins of HDL. ApoC-I, apoC-II, apoC-III, and apoE are present in all lipoproteins in 
different proportions. These apoproteins have various functions and help in the metabolic 
pathways of lipoprotein metabolism such as the activation of specific enzymes and the sta-
bilization of the lipoprotein structure and recognized by cell surface of specific cells/ tissues. 
Among different types of apolipoproteins, ApoE has a crucial importance due to its link with 
cardiovascular diseases.
1.1. ApoE and its relationship with cholesterol metabolism
Apolipoprotein (apo) E is synthesized mainly by the liver, and less is produced by other 
cell types such as macrophages. It has a great biological and biomedical importance in lipid 
metabolism such as cholesterol transportation, triglyceride metabolism, and lipoprotein 
metabolism. It is a structural component of plasma chylomicrons, very low-density lipopro-
teins (VLDL) and high-density lipoproteins (HDL), and a ligand for apo B/E (LDL) receptor 
and LDL receptor-related protein (LRP) [1]. It also facilitates the interlocation of lipoproteins 
with proteoglycans. ApoE consists of 299 amino acid residue and has three common isoforms 
apoE2, apoE3, and apoE4 which differ structurally by two amino acid substitutions at resi-
dues 112 and 158: ApoE2 (Cys112, Cys158), ApoE3 (Cys112, Arg158), and ApoE4 (Arg112, 
Arg158) [2]. Each isoform is encoded by three different apoE alleles (ɛ2, ɛ3, and ɛ4), resulting 
in six different genotypes (E2/2, E3/2, E4/2, E3/3, E4/3, and E4/4) [3] (Figure 1).
ApoE consists of two functional domains joined by a flexible hinge region: an amino-terminal 
domain that contains a highly positively charged receptor-binding region composed mainly 
of arginine and lysine residues, and a carboxyl-terminal domain which includes a lipid-
binding region. Substitutions of two amino acid residues in the three ApoE isoforms signifi-
cantly alter their receptor-binding and lipid-binding affinities and lead to differences in lipid 
metabolism [4]. ApoE2 has a lower-binding affinity for low-density lipoprotein (LDL) recep-
tors compared to ApoE3 and ApoE4. ApoE3 and ApoE4 bind similarly to the LDLR; however, 
compared to apoE3, apoE4 reduces plasma cholesterol less in humans which makes ApoE4 
pro-atherogenic lipoprotein than others. Further, ApoE2 and ApoE3 preferentially bind to 
small, phospholipid-enriched high-density lipoproteins (HDL), whereas ApoE4 preferentially 
binds to larger, triglyceride-enriched lipoproteins [5, 6]. ApoE isoforms have different bind-
ing affinities to different lipoproteins such as ApoE4 that exhibits a better lipid-binding abil-
ity with the VLDL particle than apoE3, whereas apoE3 binds preferentially to high-density 
lipoprotein (HDL) [7].
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The three-dimensional structure of apoE differs by Cys-Arg substitution, which causes changes 
in lipoprotein binding. The human apoE molecule contains the LDLR recognition site in the 
N-terminal helix bundle domain (residues 1–191) and initiates lipid binding by a C-terminal 
domain (residues 192–299). The substitution Cys and Arg residues, which differentiates apoE3 
and apoE4 in the helix bundle domain, leads to different organizations of the segment spanning 
residues 261–272 which plays a critical role in the interaction with lipid surfaces; this structural 
change is the basis for the preferential binding of apoE4 to VLDL than of apoE3 [8–10]. The rela-
tive lipid- and lipoprotein-binding abilities of apoE3 and apoE4 have important consequences 
for the distribution of cholesterol between the VLDL and HDL fractions of plasma [11].
To date, several epidemiological studies have investigated the relationship between apoE 
polymorphism and coronary artery disease (CAD) risk, with a significant association [12–17]. 
It has been shown that apoE polymorphism may contribute to the plasma LDL cholesterol 
level and apolipoprotein B concentration in the various populations. The effects of apoE geno-
types on coronary risk might also be explained as not only the receptor affinity or lipid lev-
els but also apolipoprotein concentrations affecting the CAD phenotype. To the best of our 
knowledge, it has been shown that the ε2 allele is associated with lower levels of total plasma 
cholesterol (TC), LDL cholesterol (LDL-C), and apolipoprotein B (apo B) and with elevated 
levels of triglycerides (TG) as compared to the ε3 allele. An elevated level of TG is related with 
the impaired clearance of remnant particles containing apo ε2, which might be due to a defec-
tive receptor recognition of those particles. Reduced levels of apo B and LDL cholesterol in 
E2/2 and E2/3 individuals are results of impaired conversion of the intestinal VLDL particles 
to LDL by interfering with normal lipolytic processing [18, 19]. On the other hand, the ε4 allele 
Figure 1. The schematic representation of the structural and functional domains of human apolipoprotein E (ApoE) isoforms.
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is associated with higher levels of total and LDL-C and apo B because particles with carriers 
of that allele have a faster catabolic rate than the ε3 counterparts [20]. Meta-analysis has been 
emphasized that ε2 carriers had a 20% reduced coronary risk as compared to ε3/ε3 genotype 
[21]. The precise mechanism may be explained by the binding affinity of apoE2 isoform to 
heparin and small, phospholipid-enriched HDL. These effective binding mechanisms enhance 
remnant lipoprotein metabolism and also reverse cholesterol transport [5–22]. Further, apo E2 
isoforms bind to LDL receptors much more weakly than apo E3 or apo E4 counterparts. Apo 
E4 isoforms are also related with an increased cholesterol absorption and statin hyporespon-
siveness. However, meta-analysis has been suggested that ApoE genetic testing contributes to 
little information for statin treatment [23].
Numerous effects of apoE genotypes on coronary risk might also be explained by influences 
on additional lipid-related phenotypes such as lipoprotein subtypes, markers of inflamma-
tion, immunity, or oxidative status.
Recently, the atherogenicity of LDL and HDL subclasses and their relationship to coronary 
heart disease has taken more attention. Various studies revealed that small, dense LDL is more 
atherogenic and associated with an increased risk of CHD [24, 25] with a high triglyceride level 
[26]. Researchers reported confusing results about apoE genotypes and LDL, HDL subtypes. 
Some studies stated a relationship between ε2 allele and smaller LDL particles compared to 
ε4 allele carriers [27, 28]; others reported contradictory results [29, 30]. As we know that the 
relationships between apo E polymorphism, serum lipids, and CHD were differed due to dif-
ferent ethnicities, lifestyles, diet habits, and even to age. Epidemiological studies showed that 
men have more atherogenic profile than women with a low level of HDL cholesterol and an 
increased triglyceride level. The incidence of first cardiovascular events is also higher among 
young men and is increasing very fast along with age, than in women [31]. The effect of apo E 
allelic variants on lipids and lipoprotein particle sizes has been studied in many populations 
[28, 30, 32, 33]. Several studies suggested that the apo E polymorphism influences lipoprotein 
particle size and might indirectly increase the CHD risk differently for each gender. Topic and 
his friends stated that apo ε carriers and its relationship with lipoprotein subtypes differed 
among sex; men with ε2 allele had the smaller LDL particles and a higher TG/HDL-C ratio [1]. 
Further, Dobiasova and Frohlich proposed that the Log (TG/HDL-C) be called “atherogenic 
index of plasma” and used as a marker of plasma atherogenicity because this ratio showed a 
strong inverse correlation with LDL size [34]. Some researchers have reported an increased 
LDL-C concentration and a decreased LDL size in subjects with ε4 allele [30]. On the women 
side, studies showed an association of the ε4 allele with smaller HDL particle and a higher 
frequency of small HDL phenotype and Framingham Risk Score (“intermediate”). Further, 
the presence of the ε4 alleles is found to be the independent factor for HDL size variation in 
women. Others reported different results with ε4 allele; carrier women had the small HDL 
particles which relates with the severity of CHD [27, 35, 36].
1.2. Endothelial dysfunction and cardiovascular diseases
Despite the strong evidences about lipoproteins and apolipoproteins, it has been shown that 
chronic oxidative stress and inflammatory changes in the vascular tissue play a crucial role in 
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coronary atherosclerosis pathogenesis. Endothelium controls the normal vasomotor balance, 
the inhibition and stimulation of smooth muscle cell proliferation, migration, thrombogenesis, 
and fibrinolysis. When these functions of endothelium are impaired, endothelial dysfunction 
occurs and leads to damage of the wall. Damage to the endothelium promotes substan-
tial events and provokes atherosclerosis by increasing endothelial permeability, platelet 
aggregation, and leukocyte adhesion.
The early lesion of atherosclerosis results in the focal accumulation of lipoproteins in the inti-
mal layer of the artery. The intimal layer contains smooth muscle cell which is embedded in 
the extracellular matrix, so lipoprotein accumulation often associates with proteoglycans of 
the arterial extracellular matrix such as heparin sulfate, keratan sulfate, or chondroitin sulfate. 
These proteoglycan molecules increase the retention of lipoprotein particles in the arterial bed 
and permit their chemical modification. The extracellular bed of arterial wall is particularly 
susceptible to oxidative modification. The modification of lipids leads to hydroperoxides, lyso-
phospholipids, oxysterol, and oxidized phospholipids formation which are other stimulators 
of arterial lesion progression. On the other hand, the apoprotein part of the lipoproteins may 
undergo similar chemical modification which performs irregular protein moieties that have a 
pro-inflammatory role during lesion development. The irregular changes of the arterial wall 
might also activate mononuclear phagocytes. These phagocytes as well as vascular endothelial 
and smooth muscle cells can produce reactive oxygen species when activated. Then, reactive 
oxygen species can induce smooth muscle cell growth and trigger inflammatory response.
The second step of the lesion formation is leukocyte recruitment which is the main cell of ath-
eroma of the mononuclear lineage: monocytes and lymphocytes. The vascular endothelium 
synthesizes certain biomolecules for a regular vascular function. Various adhesion molecules 
or receptors are synthesized on the endothelial cell surface for leukocytes such as vascular 
adhesion molecule I (VCAM-I), intercellular adhesion molecule I (ICAM-I), and P-selectin. In 
normal arteries, the laminar shear stress suppresses the expression of adhesion molecules and 
stimulates adequate nitric oxide (NO) to maintain vasodilatation. Further, NO production can 
control adhesion molecules expression such as VCAM-I and show an anti-inflammatory effect. 
Reactive oxygen species may also react with NO, reduce NO bioavailability, and improve vas-
cular damage indirectly by disrupting adhesion molecule express. In addition to relationship 
between adhesion molecules and NO, in vitro studies have shown that this relationship is 
attenuated by apoE [37, 38]. Recently, Ma et al. reported a reduced VCAM-1 and ICAM-1 gene 
expression in the whole aorta of hyperlipidemic mice at the sub-physiological levels of plasma 
apoE [39]. As a result of an increased adhesion of certain key molecules to endothelial cells, this 
leads to the penetration of monocytes and lymphocytes to the subendothelial layer. Besides 
modified lipoproteins, mediators of inflammation, cytokines can also regulate adhesion mol-
ecule expression and promote leukocyte recruitment. For example, VCAM-I and ICAM-I 
expressions on endothelial cells are stimulated by cytokine interleukin-I (IL-1) and tumor 
necrosis factor α (TNF-α). As mentioned earlier, the different pathways perform a cumula-
tive effect on endothelial dysfunction and lesion formation. In the intima, the recruitment of 
mononuclear phagocytes differentiates to macrophages which promote the lipid-loaded foam 
cell formation. Foam cells have two different features: they either can go to apoptotic pathway 
or produce cytokines and growth factors which lead to further complicated cellular events 
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in complicated lesion. Growth factors (platelet growth factor, fibroblast growth factor, etc.) 
and cytokines again stimulate smooth muscle cell proliferation and induce extracellular matrix 
formation. Among numerous growth factors, some of them solely trigger interstitial collagen 
production by smooth muscle cells. These mediators induce lesion progression by inducing 
transformation of fatty streak into a more complicated lesion with a high fibrous tissue and 
extracellular matrix by using either paracrine or autocrine pathway. As well as the effect of 
traditional risk factors and local mediators of various cell types, coagulation and thrombosis 
also contribute to lesion progression.
Endothelium serves as a barrier between circulating blood and its surrounding tissue. A 
transmembrane receptor tissue factor (TF) is expressed by blood vessels. An injury of the 
vascular endothelium leads to exposure of TF and activates the clotting cascade. The imbal-
ance of hemodynamics might also effect the normal activity of endothelial cells. Endothelial 
cells control platelet function via the synthesis and secretion of Von Willebrand factor (vWF). 
The vWF is an important glycoprotein in the regulation of hemostasis, stored also in platelets, 
and can be released as a response to prothrombotic and inflammatory factors. It is a bridge 
between platelet adhesion and coagulation. VWF contains functional domains for collagen, 
platelet (GPIb binding), and factor VIII binding. At the site of injury, VWF recognizes collagen 
in the subendothelial matrix, steer platelet adhesion via collagen, and GPIb-binding sites. Its 
level increases in plasma as a result of endothelial damage. vWF increases platelet adhesion 
to subendothelial layer and contributes to thrombus formation [40, 41].
The other anticoagulant functions of the endothelium are inhibition of coagulation by TFPI, 
keeping balance between thrombin- thrombomodulin secretion and regulation of coagulation 
factors by antitrypsin. On the other hand, the endothelium controls the activation and regu-
lation of fibrinolysis by the secretion of tPA and PAIs. tPA is released in response to throm-
bin which is controlled by PAI-1. Various complex functions of endothelium are controlled 
strictly with high fidelity to maintain vascular health.
Based on the robust relationship between lipoprotein metabolism and basic endothelium func-
tions, it has been recommended that different types of inflammatory reactions might be involved 
in the initiation and progression stages of atherosclerosis and contribute to vascular events.
Numerous epidemiologic studies reported that 20% of the coronary events occurred in the 
absence of the classical risk factors: hyperlipidemia, diabetes, hypertension, and smoking. 
In this situation, a question raises whether traditional risk factors are adequate to predict 
CVD risk. To solve this issue, new biomarkers are proposed for daily practice for better iden-
tification of the risk, including hemostatic system markers (the best identified ones, tissue 
plasminogen activator inhibitor—PAI-I, tissue plasminogen activator—tPA, fibrinogen, von 
Willebrand Factor—vWF, etc.) and inflammatory markers (high sensitive C reactive protein—
HsCRP, lipoprotein-associated phospholipase II—Lp-PLA2, myeloperoxidase, pentraxin 
III—PTX3, serum amyloid A, etc.). Together with these, interleukins, inflammatory cytokines, 
adhesion molecules, homocysteine, and heat shock proteins can be used as appropriate. All 
these factors participate in the atherosclerotic process and show an abnormal behavior in 
individuals at high risk, or suffered from a cardiovascular event.
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1.3. Vascular inflammation as a risk factor for cardiovascular diseases
Among the wide range of markers, C-reactive protein (CRP) was recommended as a com-
prising marker for the evaluation of CVD risk in 2009 by the common declaration of the 
Laboratory Medicine Practice Guideline of National Academy of Clinical Biochemistry 
(NACB) and American Heart Association and the CDC (AHA/CDC) [42]. CRP is an acute-
phase protein, which is primarily produced in the liver during acute inflammation or infec-
tion. CRP is stimulated by interleukin 6 (IL-6) and also detected at local sites of inflammation 
or injury. It is not specific for vascular inflammation. Then, more sensitive types of CRP have 
been developed to detect the small changes of the protein, called hs-CRP. Since hs-CRP has 
been increased, the predictive accuracy of risk evaluation with other risk-scoring systems is 
still inadequate. Hs-CRP levels are known to be systemic inflammatory marker and increased 
by infection and tissue damage, malignancies, obesity, aging, hypertension, diabetes mellitus, 
smoking, and other cardiovascular risks [43].
As described earlier, the increased expression of endothelial adhesion molecules, which 
trigger subendothelial penetration of LDL, is more susceptible to oxidation and stimulates 
inflammatory cytokines. Great attention has been recently given to myeloperoxidase (MPO), 
released systemically and locally by activated leukocytes. It has been shown that this enzyme 
is present in atherosclerotic lesions with higher concentrations and also contributes to LDL 
oxidation by different mechanisms via radical and non-radical mechanisms either lipid or 
apoprotein moieties [44]. Moreover, MPO limits the bioavailability of nitric oxide (•NO) and 
contributes to endothelial dysfunction [45, 46]. Unlike CRP, MPO is more involved in dif-
ferent stages of atherosclerosis such as foam cells, endothelial dysfunction and apoptosis, 
the activation of matrix metalloproteinases, and the expression of tissue factor which could 
address the patients with vulnerable plaques, and the potential burden of such plaques in 
clinical practice [47]. The members of the inflammatory cytokine family IL-6 and tumor necro-
sis factor (TNF)-α, released from the main cells of the plaque, vascular smooth muscle cells, 
endothelial cells, monocytes, and macrophages, are highly involved in atherosclerosis [48]. 
Ridker and colleagues reported from 14,916 healthy male; blood IL-6 concentrations were 
significantly elevated in individuals who had myocardial infarction as compared with those 
who did not [49]. Another prospective study reported a relationship between IL-6 levels and 
the incidences of ischemic cardiac disease, stroke, and heart failure events from middle-aged 
participants [50]. The other important player of the inflamed plaque is chemokines, leading 
to the recruitment of leukocytes to the damaged area of the arterial wall, as well as other 
systemic inflammatory markers, particularly monocyte chemoattractant protein 1 (MCP-1), 
which is again non-specific for interpreting CV risk [51].
Lipoprotein-associated phospholipase A2 (Lp-PLA2) or platelet-activating factor acetylhydro-lase is a unique pro-inflammatory biomarker, specific for vascular inflammation and atheroscle-
rosis [52, 53]. Lp-PLA2 was discovered in 1980, and it was classified as a Ca2+-independent PLA2 [54] produced by a wide range of inflammatory and non-inflammatory cells [55] (Figure 2).
Lp-PLA2 shows a positive correlation with CV events by various scientific and clinical stud-ies [56–58]. Lavi et al. found that patients with early coronary atherosclerosis had higher 
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lysophosphatidylcholine when compared with control subjects [59]. Herrmann et al. showed 
that carotid artery plaques of patients with cardiac events presented higher Lp-PLA2, lyso-
phospholipids, macrophage, and collagen content when compared to patients without events 
[60]. Kuniyasu et al. demonstrated that oxLDL and, particularly, the lysophosphatidylcholine 
present in this particle enhance the plasminogen activator inhibitor-1 expression [61].
Moreover, the difference in the distribution and association of Lp-PLA2 activity and index with apoB containing lipoproteins across lipoprotein subfractions has also been reported [62]. 
Further, Lp-PLA2 has been recommended as an adjunct to traditional risk factors for individu-als at a moderate or a high CV risk by the Adult Treatment Panel III (ATP III) guideline [63].
Lp-PLA2 is synthesized mainly by macrophages of atherosclerotic plaque, then enters the cir-culation, and binds to LDL, HDL, and Lp(a). In the atherosclerotic plaque, Lp-PLA2 hydro-lyzes oxLDL into Lyso-PC and oxidized nonesterified fatty acids (oxNEFAs), both of which 
have a pro-inflammatory role (Figure 3). The degradation products, Lyso-PC and oxNEFAs, 
hydrolyzed by Lp-PLA2 play crucial roles on the development of atherosclerosis. Both Lyso-PC and oxNEFAs induce the recruiting of leukocytes, upregulating inflammatory cytokine such 
as TNF-a and IL-6, amplifying oxidation, and increasing matrix metalloproteinase expres-
sion. During the process, the presence of OxLDL, as well as lysophospholipids and oxNEFAS, 
stimulates the growth of the plaque [64, 65]. As mentioned earlier, Lp-PLA2 resides on differ-
ent types of lipoproteins, so dyslipidemia effects the enzyme mass and activity and alters its 
Figure 2. Relationship of Lp-PLA2 action with phospholipids. Platelet-activating factor (PAF) is an active phospholipid 
related to many pathologic and physiologic reactions. The PAF is formed through two reactions: firstly, the cytosolic 
phospholipase A2 (cPLA2) acts on membrane phospholipids producing lysophospholipids; then, the lysophospholipids 
are modified by PAF acetyltransferase, Thus, PAF concentration is modulated by Lp-PLA2 activity.
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distribution between apo B- and apo AI-containing lipoproteins, as reported by Tsimihodimos 
et al. The same study also demonstrated inducing the increase of HDL-Lp-PLA2 activity and 
the reduction of LDL-Lp-PLA2 activity by atorvastatin treatment [66].
Lp-PLA2 quantitatively reflects the degree of inflammatory reaction of the plaque in the plasma. Lp-PLA2 measurement can be classified into enzyme activity and enzyme mass; however, Berglund and colleagues recommended an integrated measure of Lp-PLA2 activity and mass as Lp-PLA2 index which showed an independent predictor of CAD in different ethnicity [58]. Since the first report, many epidemiological studies and meta-analysis have also proved the 
significant associations between Lp-PLA2 atherogenesis and CV-risk stratification [52, 67, 68]. A meta-analysis of 32 clinical studies evaluated the association of Lp-PLA2 mass or activity with the future risk of CHD, emphasizing strongly that Lp-PLA2 is a reliable indicator for the future CV-risk assessment. The study also revealed that the association of the enzyme activity with lipid 
markers is stronger than the association with mass [69]. Further, Gungor et al. demonstrated 
an association between apoE genotype and Lp-PLA2, for the first time. The Lp-PLA2 index, an integrated measure of Lp-PLA2 mass and activity, was higher in apo E4 carriers irrespective of ethnicity and underlines the importance of assessing the relationship between genetic predis-
position and inflammation, in the assessment of cardiovascular disease risk [70]. The genetic 
variation of Lp-PLA2 activity and mass and relationship with 13 common single nucleotide poly-morphisms (SNPs) of the PLA2G7 gene was investigated in the community-based Framingham 
Heart Study. The study reported that Lp-PLA2 activity is influenced by variation in the genomic 
region of PLA2G7. Further, it has been underlined that different pathophysiological roles of 
Lp-PLA2 activity and mass conveyed different clinical outcome. The strong association is seen for Lp-PLA2 activity with cardiovascular risk factors compared to Lp-PLA2 mass [71].
Pentraxin 3 (PTX3) is a protein from acute-phase reactant family. It belongs to long pentraxins and 
possesses numerous properties in the field of inflammation. Pentraxin 3 transcription is upregu-
lated by tumor necrosis factor and interleukins (IL-1) in different cell types such as endothelial cells, 
phagocytes, smooth muscle cells, and fibroblasts which are involved in the different stages of ath-
erosclerosis. PTX3 represents a specific and sensitive marker connecting inflammation with CVD. 
Figure 3. The role of Lp-PLA2 on atherosclerotic plaque.
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During inflammation, the blood vessel produces large amounts of PTX3; its high level in circu-
lation related with pathological conditions affects cardiovascular system. Recently, epidemio-
logical and clinical data showed that PTX3 is a valid biomarker for atherosclerosis [72] and its 
high plasma levels were found to be related with the severity of coronary atherosclerosis [34]. 
It has been demonstrated that PTX3 increases the tissue factor (TF) expression in mononuclear 
and endothelial cells. The increased level of TF activates the coagulation cascade and causes the 
thrombus formation [73]. PTX3 might also bind to growth factor 2 (FGF2) and interfere with 
plaque stability via effect of the proliferation and migration of smooth muscle cells [74]. Based 
on such findings, PTX3 is more specific for coronary plaque instability than for atherosclerosis. 
In addition, the elevated plasma level of PTX3 has been found in patients with high systolic 
and diastolic blood pressure levels [75]. On the other hand, in patients with acute myocardial 
infarction, PTX3 was shown to be produced by the neutrophils penetrating into unstable coro-
nary plaques. This underscored the fact that PTX3 might be more accurate predictor of cardio-
vascular events after myocardial infarction than other markers [76].
As conclusion, it is well known that atherosclerosis is a chronic inflammatory disease of the ves-
sel wall. This chapter reviewed the relationship between atherosclerosis and the various effects of 
different inflammatory biomarkers and possible roles of genetic predisposition on the develop-
ment and progression of coronary artery diseases (Figure 4). Atherosclerotic disease mostly starts 
Figure 4. Inflammatory markers secreted from various cells in atherosclerotic lesion. Pro-inflammatory markers such 
as cytokines, pentraxin-3, MMPs, and LOX-1 are produced by macrophages, endothelial cells, and vascular smooth 
muscle cells in atherosclerotic lesion. CRP is mainly produced in the liver stimulated by IL-6. CRP indicates C-reactive 
protein; IL-6, interleukin-6; LDL, low-density lipoprotein; LOX-1, lectin-like oxidized LDL receptor-1; and MMP, matrix 
metalloproteinase.
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as asymptomatic, however, when it gives symptoms; the life quality is effected significantly and 
sometimes it will be life threatening. In these circumstances, the early detection of the disease or 
prediction of the individuals with a high CV risk becomes very important. The evaluation of a CV 
risk or a disease progression by an accurate biomarker either vascular inflammation or genetic 
markers would be promising and underscores their diagnostic importance in clinical practice.
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